COMPANY
HistaPharma Sp. z o.o. was set up in April 2018 and it is is aimed on development of medicinal products in the the area of respiratory and allergic diseases to deliver innovative solutions for better treatment. The solution provided by HistaPharma will improve the quality of life and ensure high effectiveness and safety of therapy.
COMPANY
HistaPharma is a public - private investment. The Company’s shareholder is Bridge Alfa by YouNick Mint supported by National Centre for Research and Development.
Our Services
As part of current and future activities, the company will develop medicines in therapy
MARKET FOCUS
The segment of medicinal products in a global or even local perspective are multi-billion markets for each therapeutic group. The value of sales of pharmaceutical companies in the world is, according to data for 2017, over USD 1,100 billion. For the Histapharma medical product, the first target market is the area of treatment of allergic diseases.
Contact Us
We invite our business partners for cooperation in licensing-in model or delivering final product for further distribution. We strive to meet the needs of every client on an individual basis. If you have any questions please don’t hesitate to contact us.
HistaPharma Sp. z o.o.
Say Hello!
Nazwa Grantobiorcy: HISTAPHARMA SP. Z O.O.
nr projektu: POIR.01.03.01-00-0084/16
Nazwa programu:
- Program Operacyjny Inteligentny Rozwój 2014-2020
- Działanie 1.3: Prace B+R finansowane z udziałem funduszy kapitałowych
- Poddziałanie 1.3.1: Wsparcie projektów badawczo-rozwojowych w fazie preseed przez fundusze typu proof of concept – Bridge Alfa
PARTNERS
